Multiple PI3K inhibitors have been developed for solid tumors, though as previously described, pan-PI3K inhibition (PI3K isoforms α, β, γ, and δ) in ER+ breast cancer has yielded negative trial results [95, 96, 101,148, 149]. This evidence concerns the gene PIK3CA and breast cancer.